Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61


Macrophages are exploited from an innate wound healing response to facilitate cancer metastasis.

Muliaditan T, Caron J, Okesola M, Opzoomer JW, Kosti P, Georgouli M, Gordon P, Lall S, Kuzeva DM, Pedro L, Shields JD, Gillett CE, Diebold SS, Sanz-Moreno V, Ng T, Hoste E, Arnold JN.

Nat Commun. 2018 Jul 27;9(1):2951. doi: 10.1038/s41467-018-05346-7.


Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast cancers.

Grigoriadis A, Gazinska P, Pai T, Irhsad S, Wu Y, Millis R, Naidoo K, Owen J, Gillett CE, Tutt A, Coolen AC, Pinder SE.

J Pathol Clin Res. 2018 Jan 8;4(1):39-54. doi: 10.1002/cjp2.87. eCollection 2018 Jan.


Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer.

Muliaditan T, Opzoomer JW, Caron J, Okesola M, Kosti P, Lall S, Van Hemelrijck M, Dazzi F, Tutt A, Grigoriadis A, Gillett CE, Madden SF, Burchell JM, Kordasti S, Diebold SS, Spicer JF, Arnold JN.

Clin Cancer Res. 2018 Apr 1;24(7):1617-1628. doi: 10.1158/1078-0432.CCR-17-2587. Epub 2018 Jan 16.


Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study.

Lawler K, Papouli E, Naceur-Lombardelli C, Mera A, Ougham K, Tutt A, Kimbung S, Hedenfalk I, Zhan J, Zhang H, Buus R, Dowsett M, Ng T, Pinder SE, Parker P, Holmberg L, Gillett CE, Grigoriadis A, Purushotham A.

Breast Cancer Res. 2017 Oct 13;19(1):113. doi: 10.1186/s13058-017-0881-y.


RORγt+ Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers.

Irshad S, Flores-Borja F, Lawler K, Monypenny J, Evans R, Male V, Gordon P, Cheung A, Gazinska P, Noor F, Wong F, Grigoriadis A, Fruhwirth GO, Barber PR, Woodman N, Patel D, Rodriguez-Justo M, Owen J, Martin SG, Pinder SE, Gillett CE, Poland SP, Ameer-Beg S, McCaughan F, Carlin LM, Hasan U, Withers DR, Lane P, Vojnovic B, Quezada SA, Ellis P, Tutt AN, Ng T.

Cancer Res. 2017 Mar 1;77(5):1083-1096. doi: 10.1158/0008-5472.CAN-16-0598. Epub 2017 Jan 12.


Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.

Joshi S, Watkins J, Gazinska P, Brown JP, Gillett CE, Grigoriadis A, Pinder SE.

BMC Cancer. 2015 Jul 25;15:546. doi: 10.1186/s12885-015-1531-3.


Imaging tumour heterogeneity of the consequences of a PKCα-substrate interaction in breast cancer patients.

Weitsman G, Lawler K, Kelleher MT, Barrett JE, Barber PR, Shamil E, Festy F, Patel G, Fruhwirth GO, Huang L, Tullis ID, Woodman N, Ofo E, Ameer-Beg SM, Irshad S, Condeelis J, Gillett CE, Ellis PA, Vojnovic B, Coolen AC, Ng T.

Biochem Soc Trans. 2014 Dec;42(6):1498-505. doi: 10.1042/BST20140165. Review.


The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.

Kiuchi T, Ortiz-Zapater E, Monypenny J, Matthews DR, Nguyen LK, Barbeau J, Coban O, Lawler K, Burford B, Rolfe DJ, de Rinaldis E, Dafou D, Simpson MA, Woodman N, Pinder S, Gillett CE, Devauges V, Poland SP, Fruhwirth G, Marra P, Boersma YL, Plückthun A, Gullick WJ, Yarden Y, Santis G, Winn M, Kholodenko BN, Martin-Fernandez ML, Parker P, Tutt A, Ameer-Beg SM, Ng T.

Sci Signal. 2014 Aug 19;7(339):ra78. doi: 10.1126/scisignal.2005157.


Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles.

Gazinska P, Grigoriadis A, Brown JP, Millis RR, Mera A, Gillett CE, Holmberg LH, Tutt AN, Pinder SE.

Mod Pathol. 2013 Jul;26(7):955-66. doi: 10.1038/modpathol.2012.244. Epub 2013 Feb 8.


Biologic markers determine both the risk and the timing of recurrence in breast cancer.

Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC.

Breast Cancer Res Treat. 2011 Sep;129(2):607-16. doi: 10.1007/s10549-011-1564-5. Epub 2011 May 20.


The challenges of integrating molecular imaging into the optimization of cancer therapy.

Patel GS, Kiuchi T, Lawler K, Ofo E, Fruhwirth GO, Kelleher M, Shamil E, Zhang R, Selvin PR, Santis G, Spicer J, Woodman N, Gillett CE, Barber PR, Vojnovic B, Kéri G, Schaeffter T, Goh V, O'Doherty MJ, Ellis PA, Ng T.

Integr Biol (Camb). 2011 Jun;3(6):603-31. doi: 10.1039/c0ib00131g. Epub 2011 May 4. Review.


PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.

Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C.

Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10208-13. doi: 10.1073/pnas.0907011107. Epub 2010 May 17.


Oncological outcomes in rats given nephrocarcinogenic exposure to dietary ochratoxin a, followed by the tumour promoter sodium barbital for life: a pilot study.

Mantle PG, Dobrota M, Gillett CE, Odell EW, Pinder SE.

Toxins (Basel). 2010 Apr;2(4):552-71. doi: 10.3390/toxins2040552. Epub 2010 Mar 31.


Use of a BRCA1 peptide validates MS110 as a BRCA1-specific antibody in immunohistochemistry.

Alamshah A, Springall R, Gillett CE, Solomon E, Morris JR.

Histopathology. 2008 Jul;53(1):117-20. doi: 10.1111/j.1365-2559.2008.03049.x. Epub 2008 May 6. No abstract available.


Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival.

Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A, Easton D, Lakhani SR.

Breast Cancer Res. 2007;9(1):R4.


BRCA1 dysfunction in sporadic basal-like breast cancer.

Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN.

Oncogene. 2007 Mar 29;26(14):2126-32. Epub 2006 Oct 2.


Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast.

Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, Hanby A.

Histopathology. 2006 Jul;49(1):22-34.


Different patterns of inflammation and prognosis in invasive carcinoma of the breast.

Lee AH, Gillett CE, Ryder K, Fentiman IS, Miles DW, Millis RR.

Histopathology. 2006 May;48(6):692-701.


An alternative method of dissecting mastectomy specimens.

D'Arrigo C, Hanby AM, Springall RJ, Gillett CE, Millis RR.

Histopathology. 2006 Apr;48(5):608-9. No abstract available.



Gillett CE.

Methods Mol Med. 2006;120:191-200.


Breast tissue microarrays.

Springall RJ, Gillett CE.

Methods Mol Med. 2006;120:43-50.


A role for endothelin-2 and its receptors in breast tumor cell invasion.

Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR.

Cancer Res. 2004 Apr 1;64(7):2461-8.


MSI-low, a real phenomenon which varies in frequency among cancer types.

Halford SE, Sawyer EJ, Lambros MB, Gorman P, Macdonald ND, Talbot IC, Foulkes WD, Gillett CE, Barnes DM, Akslen LA, Lee K, Jacobs IJ, Hanby AM, Ganesan TS, Salvesen HB, Bodmer WF, Tomlinson IP, Roylance RR.

J Pathol. 2003 Nov;201(3):389-94.


Beta-catenin abnormalities and associated insulin-like growth factor overexpression are important in phyllodes tumours and fibroadenomas of the breast.

Sawyer EJ, Hanby AM, Poulsom R, Jeffery R, Gillett CE, Ellis IO, Ellis P, Tomlinson IP.

J Pathol. 2003 Aug;200(5):627-32.


Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer.

Zhu G, Reynolds L, Crnogorac-Jurcevic T, Gillett CE, Dublin EA, Marshall JF, Barnes D, D'Arrigo C, Van Trappen PO, Lemoine NR, Hart IR.

Oncogene. 2003 Jun 12;22(24):3742-8.


The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours.

Sawyer EJ, Hanby AM, Rowan AJ, Gillett CE, Thomas RE, Poulsom R, Lakhani SR, Ellis IO, Ellis P, Tomlinson IP.

J Pathol. 2002 Apr;196(4):437-44.


Mitotic counts provide additional prognostic information in grade II mammary carcinoma.

Lynch J, Pattekar R, Barnes DM, Hanby AM, Camplejohn RS, Ryder K, Gillett CE.

J Pathol. 2002 Mar;196(3):275-9.


Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast.

Gillett CE, Miles DW, Ryder K, Skilton D, Liebman RD, Springall RJ, Barnes DM, Hanby AM.

J Pathol. 2001 Apr;193(4):433-41.


Multiple tissue core arrays in histopathology research: a validation study.

Gillett CE, Springall RJ, Barnes DM, Hanby AM.

J Pathol. 2000 Dec;192(4):549-53.


Molecular markers for predicting prostate cancer stage and survival.

Dunsmuir WD, Gillett CE, Meyer LC, Young MP, Corbishley C, Eeles RA, Kirby RS.

BJU Int. 2000 Nov;86(7):869-78.


Association between loss of heterozygosity of BRCA1 and BRCA2 and morphological attributes of sporadic breast cancer.

Hanby AM, Kelsell DP, Potts HW, Gillett CE, Bishop DT, Spurr NK, Barnes DM.

Int J Cancer. 2000 Oct 15;88(2):204-8.


Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers.

Srinivasan R, Gillett CE, Barnes DM, Gullick WJ.

Cancer Res. 2000 Mar 15;60(6):1483-7.


A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells.

Lin CQ, Singh J, Murata K, Itahana Y, Parrinello S, Liang SH, Gillett CE, Campisi J, Desprez PY.

Cancer Res. 2000 Mar 1;60(5):1332-40.


Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breast.

Leong AC, Hanby AM, Potts HW, Tan DS, Skilton D, Ryder K, Harris WH, Liebmann RD, Barnes DM, Gillett CE.

Int J Cancer. 2000 Jan 20;89(1):26-31.


The biological and prognostic significance of cell polarity and E-cadherin in grade I infiltrating ductal carcinoma of the breast.

Tan DS, Potts HW, Leong AC, Gillett CE, Skilton D, Harris WH, Liebmann RD, Hanby AM.

J Pathol. 1999 Sep;189(1):20-7.


Demystified ... cell cycle.

Gillett CE, Barnes DM.

Mol Pathol. 1998 Dec;51(6):310-6. Review. No abstract available.


Cyclin D1 in breast cancer.

Barnes DM, Gillett CE.

Breast Cancer Res Treat. 1998;52(1-3):1-15. Review.


Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. CRC/BPG UK Familial Prostate Cancer Study Collaborators.

Edwards SM, Dunsmuir WD, Gillett CE, Lakhani SR, Corbishley C, Young M, Kirby RS, Dearnaley DP, Dowe A, Ardern-Jones A, Kelly J, Spurr N, Barnes DM, Eeles RA.

Int J Cancer. 1998 Sep 25;78(1):1-7.


Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia.

Gillett CE, Lee AH, Millis RR, Barnes DM.

J Pathol. 1998 Apr;184(4):396-400.


Cell proliferation measured by MIB1 and timing of surgery for breast cancer.

Cooper LS, Gillett CE, Smith P, Fentiman IS, Barnes DM.

Br J Cancer. 1998 May;77(9):1502-7.


Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters.

Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM.

Int J Cancer. 1998 Feb 20;79(1):71-5.


High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers.

Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ, Lu X.

Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6380-5.


Breast cancer--from clinic to laboratory.

Gillett CE, Happerfield LC.

Br J Biomed Sci. 1997 Mar;54(1):47-56.


Determination of cell proliferation.

Barnes DM, Gillett CE.

Clin Mol Pathol. 1995 Feb;48(1):M2-5. No abstract available.

Supplemental Content

Loading ...
Support Center